Unions, Public Interest Groups Tell Congress to Take Pharma Provision Out of NAFTA 2.0
A coalition of 70 groups -- including Public Citizen, the AFL-CIO and a nonprofit focused on reforming intellectual property to serve the poor -- is asking Congress members to cut language from the new NAFTA that would require Mexico, Canada…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
and the United States to grant a 10-year exclusivity period to biologics. Their letter, distributed Jan. 22, says, "NAFTA 2.0 includes terms that would lock in place existing U.S. policies that have led to high medicine prices, undermining the authority of this and future Congresses to implement important reforms to expand generic and biosimilar competition, lower medicine prices and expand access. This is the case because NAFTA 2.0 includes expansive terms relating to patent and other non-trade policy matters to which the U.S. Congress will be obliged to conform our domestic policies." Currently, U.S. law gives 12 years' protection to biologics.